Sono-Tek (SOTK) Q4 2026 earnings review
Margin Masterclass Masks Top-Line Stagnation
Sono-Tek achieved its eighth consecutive quarter above $5 million in revenue, closing FY26 with $20.9 million in sales (+2% YoY). While top-line growth was anemic, the bottom-line execution was spectacular. Operating income surged 81% for the year, and gross margin crossed the 51% threshold. The narrative is a tale of two sectors: the company successfully swapped collapsing Clean Energy revenue for surging, high-margin Medical device sales. However, cautious FY27 guidance calling for 'relatively flat to modestly higher' revenue suggests the Clean Energy hangover will cap near-term growth.
🐂 Bull Case
The strategic pivot from selling low-cost components to high-ASP (Average Selling Price) complete systems is permanently elevating the margin profile. Gross margins hit 51%, and operating leverage is finally kicking in.
The Medical segment grew a massive 54% to $5.0 million in FY26. Sono-Tek's balloon catheter and stent coating technology is winning in high-barrier, life-or-death production environments.
🐻 Bear Case
The Alternative Energy sector—which grew 64% in FY25 and drove the bull narrative—reversed course, falling 19% in FY26 due to government policy changes. It is no longer a reliable growth engine.
Despite a near-record $9.1 million backlog, management is guiding for 'relatively flat' FY27 revenue. This implies long conversion cycles and a lack of near-term catalysts to reignite total top-line growth.
⚖️ Verdict: ⚪
Hold. Sono-Tek's operational discipline and margin expansion are highly commendable. However, without a clear path to double-digit top-line growth, the stock's upside is constrained. The Medical segment must grow large enough to completely outrun the Clean Energy decline before a stronger conviction is warranted.
Key Themes
Medical Market Leads the Strategic Pivot
Medical sales surged 54% YoY to $5.0 million, validating management's pivot toward high-value balloon catheter and specialty stent coating applications. In previous quarters, management flagged this sector as the next growth frontier to replace cooling clean energy demand, and Q4 results prove the execution is flawless. This segment is stickier and less dependent on government subsidies.
High-ASP Strategy Driving Margins
In-Line Coating Systems (formerly Integrated Coating Systems) saw revenue explode by 91% to $7.07 million. This category represents the company's highest-ASP, production-scale equipment (often $300k-$1M+ per unit). By successfully upselling customers from R&D machines to full-scale production lines, Sono-Tek expanded gross margins from 48% to 51%.
Alternative Energy Succumbs to Macro Pressures
Alternative/Clean Energy sales dropped 19% to $7.97 million. Management explicitly blamed 'government policy shifts and elimination of incentives' for reduced electrolysis demand. This confirms concerns raised in H1 FY26 regarding customer apprehension over U.S. climate policy changes. This former star segment is now a structural headwind.
Backlog Disconnect from Guidance
Equipment and service backlog increased 5% YoY to $9.12 million, sitting at near-record levels. However, FY27 revenue guidance is 'relatively flat to modestly higher.' This contradiction suggests that the new high-ASP systems sitting in the backlog have exceptionally long build/delivery times, delaying revenue recognition well into late FY27 or FY28.
Electronics and Semiconductor Resilience
Electronics market sales increased 16% YoY to $6.29 million. Management noted strong demand for electrically active coatings in diagnostic applications. This segment provides a stable, growing baseline that helps offset the volatility seen in the Industrial and Alternative Energy segments.
Industrial Segment Continues to Bleed
Industrial sales declined another 18% in FY26 to $1.58 million, following a massive 47% drop in FY25. This segment has been persistently weak, suffering from a lack of repeating large orders (like the European glass coating order seen in prior years) and intense pressure from cheap overseas competition.
Other KPIs
Accelerating. Up from 47.5% in FY25. This 350+ basis point expansion is the highlight of the earnings report, driven entirely by a favorable product mix (high-ASP systems) and a strategic shift toward domestic U.S. buyers, which bypassed expensive international business costs.
Accelerating. An 81% YoY increase from $1.01 million. The company successfully translated its gross margin expansion directly to the bottom line, proving the operating leverage inherent in its new high-ASP business model.
Stable and pristine. The company continues to operate with zero debt. Cash and equivalents grew significantly from the $11.9 million reported at the end of FY25, providing a strong cushion against near-term macro volatility.
Guidance
Accelerating vs 1H FY26. Driven by the Medical sector and backlog conversion. However, management remains vague on the exact magnitude of this growth.
Decelerating expectation. Despite strong 1H expectations and a $9.1M backlog, full-year guidance suggests a significant drop-off or delayed order timing in the second half of FY27, specifically tied to Clean Energy uncertainty.
Key Questions
Backlog Conversion Timing
With backlog up 5% to $9.1 million, why is full-year FY27 guidance only 'flat to modestly higher'? What percentage of the current backlog is scheduled for delivery beyond FY27?
Clean Energy Bottom
Alternative Energy fell 19% due to policy shifts. Do you view the current run rate as the 'new normal' floor, or are there risks of further cancellations/delays in the existing Clean Energy pipeline?
Medical Segment Durability
The Medical segment grew 54% this year. As you transition customers from R&D to production-scale balloon catheter systems, what is the normalized, sustainable growth rate for this segment going forward?
Capital Allocation
With $14.8 million in cash, zero debt, and excellent free cash flow generation, what is the Board's appetite for increasing the share repurchase program or pursuing synergistic acquisitions?